Micrologix Announces Executive Appointments

Trading Symbol



TSE: MBI

US OTC: MGIXF



Apr 02, 2001, 01:00 ET from Micrologix Biotech Inc.

    VANCOUVER, April 2 /PRNewswire/ - Micrologix Biotech Inc. is pleased to
 announce the following senior management appointments:
 
     Arthur J. Ayres, CA            Vice President, Finance & Administration
                                    and CFO
     C. Robert Cory, Ph.D., MBA     Vice President, Business Development
     H. David Friedland, M.D.       Vice President, Clinical Development
     Patricia J. McNicol, Ph.D      Vice President, Research
 
     "It gives me great pleasure to see these dedicated professionals assume
 greater responsibility within the company," said William J. (Bud) Foran,
 President, CEO and Chairman of Micrologix. "Collectively, this group has
 served Micrologix for more than 20 years and we have benefited enormously from
 their expertise. We look forward to their continued contributions as
 Micrologix advances the commercialization of its novel anti-infectives."
     Mr. Ayres joined Micrologix in November 1994 as Controller and was
 appointed Director of Finance in February 2000. He is a Chartered Accountant
 and has a B.A. (Hon.) in Commerce and Computer Science from Simon Fraser
 University. With more than 19 years of management, finance and related
 experience, Mr. Ayres has played a vital role in Micrologix's management team
 including assisting in raising over $75 million and the listing of
 Micrologix's shares on the Toronto Stock Exchange. In addition to overseeing
 the business affairs of Micrologix, Mr. Ayres will direct Micrologix's
 financial strategy with emphasis on generating shareholder value and ensuring
 Micrologix remains well capitalized.
     Dr. Cory joined Micrologix in May 1995 as Manager, Business Development
 and was appointed Director, Business Development in November 1998. He has over
 10 years of experience in both technical and managerial positions in
 biotechnology and health science. Dr. Cory holds a Ph.D. in Biochemistry from
 the University of Waterloo and an MBA in finance and strategic planning from
 the Wilfrid Laurier School of Business and Economics. In addition to managing
 Micrologix's intellectual property portfolio, Dr. Cory directs the
 implementation of Micrologix's partnering strategy and is actively involved in
 sourcing and negotiating with potential industry partners and collaborators.
 With his joint backgrounds in science and business Dr. Cory contributes
 significantly to the Company's commercialization activities.
     Dr. Friedland joined Micrologix in January 1997 as Head, Preclinical
 Development and was appointed Director, Clinical Development in October 1999.
 After receiving his M.D., Dr. Friedland specialized in Medical Microbiology
 and received his Master of Medicine (MMED) from the University of the
 Witwatersrand, South Africa. He has 10 years of experience in clinical
 medicine, specializing in infectious disease. Dr. Friedland has been integral
 in advancing Micrologix's three drug candidates into clinical trials,
 including obtaining fast track designation from the FDA on the Company's lead
 product, MBI 226, currently in Phase III clinical trials. His responsibilities
 include directing Micrologix's clinical programs, interacting with the FDA and
 supervising the contract research organizations that conduct studies on
 Micrologix's behalf.
     Dr. McNicol joined Micrologix in January 1997 as Group Leader,
 Microbiology. She was appointed Director of Research (Acting) in November 1998
 and Director of Research in October 1999. She holds a Ph.D. in Medical
 Microbiology from the University of Manitoba. Prior to joining Micrologix, Dr.
 McNicol spent 12 years in progressively senior research and administrative
 positions in academic and public health science organizations working in the
 fields of molecular virology, epidemiology and antimicrobial resistance. She
 leads the Company's research program, including drug discovery, drug delivery
 and support of products in clinical trials. In addition, Dr. McNicol is
 involved in discussions with potential collaborators and partners from a
 research perspective.
 
     About Micrologix
     Micrologix develops novel drugs targeted at severe and life-threatening
 diseases - particularly those caused by antibiotic-resistant bacteria. The
 Company's portfolio of antibiotic drug candidates is based on improved analogs
 of naturally occurring cationic peptides found in the host defense systems of
 most life forms. Micrologix currently has three drugs in clinical trials in
 the United States: MBI 226 for preventing catheter-related bloodstream
 infections in Phase III clinical trials; MBI 594AN for treating acne in Phase
 II; and MBI 853NL for preventing hospital-acquired Staphylococcus aureus
 infections in Phase I. The Company's common shares are included in the TSE 300
 Composite Index.
 
 
                                        "William J. Foran"
                                        -------------------------------
                                        William J. (Bud) Foran
                                        Chairman, President and CEO
 
     The foregoing news release contains forward-looking statements within the
 meaning of the United States Private Securities Litigation Reform Act of 1995.
 All statements other than statements of historical fact may be deemed to be
 forward-looking statements. Forward-looking statements frequently, but not
 always use the words "expects", "anticipates", "suggests", "plans", "believes"
 or "intends", or similar words and/or include statements concerning the
 Company's strategies, goals and plans, or state that certain actions, events
 or results "will" be taken, occur or be achieved. These forward-looking
 statements involve known and unknown risks, uncertainties and other factors
 which may cause the actual results, performance or achievement of the company,
 or industry results, to be materially different from any future results,
 performance or achievements expressed or implied by such statements. Such
 factors include, among others, those described in the Company's annual report
 on Form 20-F, including the following: uncertainties related to early stage of
 development, technology and product development; dependence on future
 corporate collaborations; dependence on proprietary technology and uncertainty
 of patent protection; management of growth; future capital needs and
 uncertainty of additional funding; intense competition; manufacturing and
 market uncertainties; government regulation; product liability exposure and
 insurability.
 
     The Toronto Stock Exchange and the Canadian Venture Exchange have not
 reviewed and do not accept responsibility for the adequacy or accuracy of this
 release.
 
 

SOURCE Micrologix Biotech Inc.
    VANCOUVER, April 2 /PRNewswire/ - Micrologix Biotech Inc. is pleased to
 announce the following senior management appointments:
 
     Arthur J. Ayres, CA            Vice President, Finance & Administration
                                    and CFO
     C. Robert Cory, Ph.D., MBA     Vice President, Business Development
     H. David Friedland, M.D.       Vice President, Clinical Development
     Patricia J. McNicol, Ph.D      Vice President, Research
 
     "It gives me great pleasure to see these dedicated professionals assume
 greater responsibility within the company," said William J. (Bud) Foran,
 President, CEO and Chairman of Micrologix. "Collectively, this group has
 served Micrologix for more than 20 years and we have benefited enormously from
 their expertise. We look forward to their continued contributions as
 Micrologix advances the commercialization of its novel anti-infectives."
     Mr. Ayres joined Micrologix in November 1994 as Controller and was
 appointed Director of Finance in February 2000. He is a Chartered Accountant
 and has a B.A. (Hon.) in Commerce and Computer Science from Simon Fraser
 University. With more than 19 years of management, finance and related
 experience, Mr. Ayres has played a vital role in Micrologix's management team
 including assisting in raising over $75 million and the listing of
 Micrologix's shares on the Toronto Stock Exchange. In addition to overseeing
 the business affairs of Micrologix, Mr. Ayres will direct Micrologix's
 financial strategy with emphasis on generating shareholder value and ensuring
 Micrologix remains well capitalized.
     Dr. Cory joined Micrologix in May 1995 as Manager, Business Development
 and was appointed Director, Business Development in November 1998. He has over
 10 years of experience in both technical and managerial positions in
 biotechnology and health science. Dr. Cory holds a Ph.D. in Biochemistry from
 the University of Waterloo and an MBA in finance and strategic planning from
 the Wilfrid Laurier School of Business and Economics. In addition to managing
 Micrologix's intellectual property portfolio, Dr. Cory directs the
 implementation of Micrologix's partnering strategy and is actively involved in
 sourcing and negotiating with potential industry partners and collaborators.
 With his joint backgrounds in science and business Dr. Cory contributes
 significantly to the Company's commercialization activities.
     Dr. Friedland joined Micrologix in January 1997 as Head, Preclinical
 Development and was appointed Director, Clinical Development in October 1999.
 After receiving his M.D., Dr. Friedland specialized in Medical Microbiology
 and received his Master of Medicine (MMED) from the University of the
 Witwatersrand, South Africa. He has 10 years of experience in clinical
 medicine, specializing in infectious disease. Dr. Friedland has been integral
 in advancing Micrologix's three drug candidates into clinical trials,
 including obtaining fast track designation from the FDA on the Company's lead
 product, MBI 226, currently in Phase III clinical trials. His responsibilities
 include directing Micrologix's clinical programs, interacting with the FDA and
 supervising the contract research organizations that conduct studies on
 Micrologix's behalf.
     Dr. McNicol joined Micrologix in January 1997 as Group Leader,
 Microbiology. She was appointed Director of Research (Acting) in November 1998
 and Director of Research in October 1999. She holds a Ph.D. in Medical
 Microbiology from the University of Manitoba. Prior to joining Micrologix, Dr.
 McNicol spent 12 years in progressively senior research and administrative
 positions in academic and public health science organizations working in the
 fields of molecular virology, epidemiology and antimicrobial resistance. She
 leads the Company's research program, including drug discovery, drug delivery
 and support of products in clinical trials. In addition, Dr. McNicol is
 involved in discussions with potential collaborators and partners from a
 research perspective.
 
     About Micrologix
     Micrologix develops novel drugs targeted at severe and life-threatening
 diseases - particularly those caused by antibiotic-resistant bacteria. The
 Company's portfolio of antibiotic drug candidates is based on improved analogs
 of naturally occurring cationic peptides found in the host defense systems of
 most life forms. Micrologix currently has three drugs in clinical trials in
 the United States: MBI 226 for preventing catheter-related bloodstream
 infections in Phase III clinical trials; MBI 594AN for treating acne in Phase
 II; and MBI 853NL for preventing hospital-acquired Staphylococcus aureus
 infections in Phase I. The Company's common shares are included in the TSE 300
 Composite Index.
 
 
                                        "William J. Foran"
                                        -------------------------------
                                        William J. (Bud) Foran
                                        Chairman, President and CEO
 
     The foregoing news release contains forward-looking statements within the
 meaning of the United States Private Securities Litigation Reform Act of 1995.
 All statements other than statements of historical fact may be deemed to be
 forward-looking statements. Forward-looking statements frequently, but not
 always use the words "expects", "anticipates", "suggests", "plans", "believes"
 or "intends", or similar words and/or include statements concerning the
 Company's strategies, goals and plans, or state that certain actions, events
 or results "will" be taken, occur or be achieved. These forward-looking
 statements involve known and unknown risks, uncertainties and other factors
 which may cause the actual results, performance or achievement of the company,
 or industry results, to be materially different from any future results,
 performance or achievements expressed or implied by such statements. Such
 factors include, among others, those described in the Company's annual report
 on Form 20-F, including the following: uncertainties related to early stage of
 development, technology and product development; dependence on future
 corporate collaborations; dependence on proprietary technology and uncertainty
 of patent protection; management of growth; future capital needs and
 uncertainty of additional funding; intense competition; manufacturing and
 market uncertainties; government regulation; product liability exposure and
 insurability.
 
     The Toronto Stock Exchange and the Canadian Venture Exchange have not
 reviewed and do not accept responsibility for the adequacy or accuracy of this
 release.
 
 SOURCE Micrologix Biotech Inc.